Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter, Editor-in-Chief Nielsen Hobbs and Generics Bulletin Executive Editor Dave Wallace discuss US Food and Drug Administration Commissioner Martin Makary’s appointment of Katherine Szarama as acting Center for Biologics Evaluation and Research director and the updated timeline for find a permanent director (:33), as well as and Makary’s approach compared to the recent Center for Drug Evaluation and Research leadership change (4:39). They also consider the impact of the US Supreme Court’s review of the generic drug skinny label policy (10:54).

#pharma #business

More On These Topics From The Pink Sheet

Alternate Leadership Strategy: Deputy Director Szarama Is Acting US FDA Biologics Center Chief: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/alternate-leadership-strategy-deputy-director-szarama-is-acting-us-fda-biologics-center-chief-P6ZJLJY7YBDUXCG6DMWNYNIHUI/

US FDA’s Makary Expects To Name Permanent CBER Director Within Weeks As Prasad Departs: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/fdas-makary-expects-to-name-permanent-cber-director-within-weeks-as-prasad-departs-37ZOLQT6FNDARGPMZOE2EI2DPE/ Skinny Label At SCOTUS: Could Generics Maintain Carve-Out Authority No Matter The Decision?: ⁠https://insights.citeline.com/pink-sheet/biosimilars-and-generics/generics/skinny-label-at-scotus-could-generics-maintain-carve-out-authority-no-matter-the-decision-54CTMA7XSBGIFF7WOYPGA26PGM/

Salvatore Viscomi, CEO and co-founder of Carna Health, discussed the company's pivotal work to combat the global crisis of chronic kidney disease (CKD).

In this episode of the China biopharma English-language podcast, Xu Hu talks about the siRNA area, including possible industry and R&D environment changes for Chinese firms developing these therapies and trends in deals of China-originated siRNA assets this year.

Story link: Chinese siRNA Contenders Set For Transitions, Deals In 2026

The Life Sciences Hub Wales supports on oncology and cardiovascular disease technologies which are ideally at TRL6. Improved health outcomes is among the aims  of the LSHW as it decides where to place its support. Chris Jones of LSHW explained the rationale to Medtech Insight at BioWales 2026.   

In the latest episode of the Over The Counter podcast, HBW Insight speaks with Ellie Adams, founder and CEO of QIVA Global – a strategy and operating partner to international consumer healthcare brands entering the Chinese market. Adams, who has spent more than two decades working in China, offers a frank, insider perspective on what it really takes to succeed in the world's second-largest consumer healthcare market. From the rise of "punk health" among Chinese youth to the fragmented social commerce ecosystem that bears little resemblance to anything in Europe or the US, Adams unpacks why some of the industry's biggest names are thriving in China while others are stumbling. The answer, she suggests, almost always comes down to one thing: a playbook built from the inside out. Timestamps: 2:00 – Introductions 4:00 – What does China’s consumer health market look like? 8:00 – Why are some firms succeeding and others struggling? 12:00 – What kinds of products do well in China? 14:00 – How do you export into China? 22:00 – What is the “positive list”? 27:00 – Is there such a thing as Rx-to-OTC switch in China? 29:00 – What are the risks of exporting to China? 35:00 – What is the future growth potential of the Chinese OTC market?

In this In Vivo podcast, David Wild speaks with Adrian Woolfson, co-founder, president and CEO of Genyro, about how high-fidelity DNA writing and AI-driven genome design could reshape biopharma R&D, from accelerating program design and iteration speed to enabling civilizational-scale applications like DNA-based data storage and ultra-fast vaccine manufacturing. Woolfson, a physician-scientist, explains why Genyro is pursuing a licensing-led business model and which transformative applications he believes will emerge first.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年4月24日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: 伊朗港口封锁对全球制药业的影响；拜耳坚守欧洲市场但寻求更多发展；凯莱拉（Kailera）的重大IPO；2025年最畅销药物；Anthropic聘请诺华CEO。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-DBDTTSHFXNBTVLT6PE4MX45B74/

Audio roundup of selected biopharma industry content from Scrip over the business week ended Apr. 24, 2026. This episode was produced with the help of AI text-to-voice and voice emulation tools.

This time – Iran blockade’s impact on global pharma; Bayer loyal to Europe but wants more; Kailera’s big IPO; 2025’s top drugs; Anthropic taps Novartis’s CEO.  

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-DBDTTSHFXNBTVLT6PE4MX45B74/

本期《中国生物技术播客》聚焦康方生物的依沃西单抗将如何改写历史，以及在PD-(L)1/VEGF双抗之间是否即将发生国内头对头三期临床试验。

   Could PD-(L)1/VEGF Agents Face Off First In China Phase III Trials?

Scrip Senior Writer Joseph Haas interviewed attorneys Kevin Cooper and Bill Roegge of Cooley LLP about recent events and trends in biopharmaceutical merger-and-acquisition activity. They discussed the current state of M&A after a busy conclusion to the first quarter and how that interplays with financing and partnering activity. In addition, Kevin offered tips for smaller companies to get good outcomes when dealing with large pharma firms, Bill talked about whether 2026 may be a year of competing bids in biopharma M&A and the discussion closed with a look at deals centered on platform technologies and their potential to replenish an acquirer's pipeline.

本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年4月17日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。

本期要闻: Icotyde或将成为强生史上最重磅产品；daraxonrasib数据助力Revolution；Travere的Filspari成为首个用于治疗FSGS的药物；GSK重金押注B7-H4抗体药物偶联物；以及礼来夺得全球制药销售额榜首。

Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KROBJCLAKVFBLCZ7BGBGCE3VDQ/